KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Kidney International

• Publication date

  2025-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.kint.2025.04.004PMID 40975564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children.

  2025cited by this paper
• KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.

  2024cited by this paper
• Are children with IgA nephropathy different from adult patients?

  2024cited by this paper
• A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.

  2024cited by this paper
• IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

  2024cited by this paper
• Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis

  2024cited by this paper
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

  2024cited by this paper
• Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy

  2024cited by this paper
• A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

  2023cited by this paper
• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.

  2023cited by this paper
• Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy

  2023cited by this paper
• Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey

  2023cited by this paper
• Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.

  2023cited by this paper
• Targeting the Endothelin A Receptor in IgA Nephropathy

  2023cited by this paper
• Long-Term Outcomes in IgA Nephropathy

  2023cited by this paper
• IgA nephropathy

  2023cited by this paper
• Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial

  2023cited by this paper
• Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial.

  2023cited by this paper
• Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy

  2023cited by this paper
• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

  2023cited by this paper
• A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.

  2023cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  2022cited by this paper
• Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

  2022cited by this paper
• Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

  2022cited by this paper
• Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.

  2022cited by this paper
• Chronic kidney disease

  2021cited by this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

  2021cited by this paper
• From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options

  2021cited by this paper
• A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.

  2021cited by this paper
• Corticosteroid therapy for nephrotic syndrome in children.

  2020cited by this paper
• Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.

  2020cited by this paper
• Immunosuppressive agents for treating IgA nephropathy.

  2020cited by this paper
• Updating the International IgA Nephropathy Prediction Tool for use in children.

  2020cited by this paper
• Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy

  2020cited by this paper
• After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

  2020cited by this paper
• Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.

  2019cited by this paper
• European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.

  2019cited by this paper
• Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

  2019cited by this paper
• Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

  2019cited by this paper
• Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

  2019cited by this paper
• Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy

  2019cited by this paper
• Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy.

  2019cited by this paper
• Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein)

  2018cited by this paper
• Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features

  2018cited by this paper
• Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study

  2018cited by this paper
• Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature

  2018cited by this paper
• Long‐term follow up of pediatric immunoglobulin A nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy

  2017cited by this paper
• Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

  2017cited by this paper
• Biomarkers and targeted new therapies for IgA nephropathy

  2017cited by this paper
• Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

  2017cited by this paper
• Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

  2017cited by this paper
• Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.

  2017cited by this paper
• Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.

  2017cited by this paper
• The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial

  2016cited by this paper
• Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

  2016cited by this paper
• Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.

  2016cited by this paper
• Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

  2016cited by this paper
• Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

  2016cited by this paper
• Endothelin

  2016cited by this paper
• Non‐Corticosteroid Immunosuppressive Medications for Steroid‐Sensitive Nephrotic Syndrome in Children

  2015cited by this paper
• Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).

  2015cited by this paper
• Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

  2015cited by this paper
• Corticosteroid therapy for nephrotic syndrome in children.

  2015cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2015cited by this paper
• A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy

  2014cited by this paper
• Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

  2014cited by this paper
• Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: A meta-analysis of randomized controlled trials

  2014cited by this paper
• Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study.

  2013cited by this paper
• Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

  2013cited by this paper
• GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence.

  2013cited by this paper
• Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schönlein Purpura (HSP)

  2013cited by this paper
• Development and validation of a prediction rule using the Oxford classification in IgA nephropathy.

  2013cited by this paper
• Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.

  2012cited by this paper
• Spontaneous remission in children with IgA nephropathy

  2012cited by this paper
• Mechanisms and treatment of CKD.

  2012cited by this paper
• Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score

  2012cited by this paper
• Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series.

  2012cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Long-term results of a randomized controlled trial in childhood IgA nephropathy.

  2011cited by this paper
• GRADE guidelines 6. Rating the quality of evidence--imprecision.

  2011cited by this paper
• Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.

  2011cited by this paper
• Non-immunosuppressive treatment for IgA nephropathy.

  2011cited by this paper
• Predicting the risk for dialysis or death in IgA nephropathy.

  2011cited by this paper
• GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.

  2011cited by this paper
• AGREE II: advancing guideline development, reporting and evaluation in health care.

  2010cited by this paper
• Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.

  2010cited by this paper
• EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria

  2010cited by this paper
• Long-term study of mycophenolate mofetil treatment in IgA nephropathy.

  2010cited by this paper
• The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

  2010cited by this paper
• Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).

  2009cited by this paper
• A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study

  2009cited by this paper
• Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

  2009cited by this paper
• Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.

  2009cited by this paper
• IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes.

  2008cited by this paper
• Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review

  2008cited by this paper
• Improved renal survival in Japanese children with IgA nephropathy

  2008cited by this paper
• Role of remission clinics in the longitudinal treatment of CKD.

  2008cited by this paper

• Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series.

  2026cites this paper
• Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis.

  2026cites this paper
• Patient and Provider Perspectives on the Patient Journey in Immunoglobulin A Nephropathy.

  2026cites this paper
• Lower proteinuria is better for patients with IgA nephropathy: a systematic review

  2026cites this paper
• Progression of immunoglobulin A nephropathy (IgAN) in a Hispanic/Latinx population in the United States

  2026cites this paper
• A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors

  2026cites this paper
• Delayed-release budesonide combined with cyclophosphamide in a patient with IgA nephropathy with eGFR < 30 mL/min/1.73 m²: A case report

  2026cites this paper
• The latest pharmacotherapeutic options for the treatment of IgA nephropathy in the pediatric population

  2026cites this paper
• IgA Nephropathy in Adults: A Review.

  2026cites this paper
• Immunoglobulin A Nephropathy: New Treatment Options.

  2026cites this paper
• AsPNA Clinical Practice Guidelines for the management of infection-related glomerulonephritis.

  2026cites this paper
• Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis.

  2026cites this paper
• Targeting the Pathogenesis of IgA Nephropathy - A New Treatment Approach?

  2026cites this paper
• Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.

  2026cites this paper
• Normal-range B-type natriuretic peptide is associated with chronic kidney disease progression independent of albuminuria in individuals with diabetes: an observational cohort study.

  2026cites this paper
• Does rs477155 Stratify Glucocorticoid Toxicity in IgA Nephropathy?

  2026cites this paper
• Kidney Disease: Improving Global Outcomes (KDIGO): navigating a rapidly changing landscape.

  2026cites this paper
• Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study

  2025cites this paper
• Advances in Complement-Targeted Therapy for IgA Nephropathy

  2025cites this paper
• Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine

  2025influential citation
• IgA-Nephropathie – Update

  2025cites this paper
• Dapagliflozin in the treatment of IgA nephropathy in a paediatric patient

  2025cites this paper
• Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.

  2025cites this paper
• Lupus and IgA nephropathy: coexistence or coincident?

  2025cites this paper
• Updates on Glomerular Diseases: A Summary of Inaugural GlomCon Hawaii 2024

  2025cites this paper
• IgA Nephropathy: An Overview of the Clinical Trials

  2025influential citation
• The association between low-grade proteinuria and adverse kidney outcomes in IgA nephropathy: A systematic review and meta-analysis

  2025cites this paper
• Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study

  2025cites this paper
• Revolutionising IgA Nephropathy Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Emerging Therapies

  2025cites this paper
• Should Histology Guide Treatment Decisions in IgA Nephropathy?

  2025cites this paper
• Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management

  2025cites this paper
• Individualized treatment effects of corticosteroids in IgA nephropathy

  2025cites this paper
• Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections

  2025cites this paper
• Iptacopan in Patients With IgA Nephropathy From East Asia

  2025cites this paper
• Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan

  2025cites this paper
• Prognostic value of albuminuria in IgA nephropathy: insights from a real-world cohort

  2025cites this paper
• The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy

  2025cites this paper
• Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy

  2025cites this paper
• Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.

  2025cites this paper
• Die Nephrologie

  year unknowncites this paper